The drugmaker AstraZeneca reported underwhelming earnings for its fourth quarter, as sales of a handful of its cancer medicines came in below investor.
Corrections & Amplifications This headline was corrected at 0731 GMT to reflect GSK PLC 4Q Pre-Items, Pre-Tax Pft GBP1.56B, not GBP8.11B Corrections &.
By Joe Hoppe GSK expects to further grow sales and earnings after its best-selling shingles vaccine Shingrix and the launch of RSV vaccine Arexvy helped the.